Approval · Notice of Compliance 777 · 2002
ACTONEL: Notice of Compliance 777
Issued December 9, 2002
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 777
- Date
- December 9, 2002
- Company
- Procter & Gamble Pharmaceuticals Canada, IncToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- New strength: 35mg film-coated tablets; new dosing regimen: once a week for the treatment of postmenopausal osteoporosis
- Therapeutic class
- Bone metabolism regulator
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ACTONEL | 02246896 | Marketed |
Medicinal ingredients
- RISEDRONATE SODIUM 35 MG per TAB